PF-Atlas › Clinical Trials › NCT06317285
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis
GSK3915393 · Phase 2
Registry ID
NCT06317285
Phase
Phase 2
Status
Terminated
Drug / intervention
GSK3915393
Sponsor
GlaxoSmithKline
Enrollment
158
Locations
56
About this trial
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06317285 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.